Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Annals of Oncology

• Publication date

  2012-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdr294PMID 21665955PMCID PMC3331733
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer.

  2013cited by this paper
• Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

  2011influential reference
• Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

  2010cited by this paper
• Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.

  2010cited by this paper
• Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2010cited by this paper
• Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

  2010cited by this paper
• Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

  2010cited by this paper
• Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

  2010cited by this paper
• The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.

  2010cited by this paper
• Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

  2010cited by this paper
• Incidence and Demographic and Tumor Characteristics of HER2-Positive Invasive Breast Cancer in a Large, Unselected Population, 2000-2006.

  2009cited by this paper
• Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

  2009cited by this paper
• Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation.

  2009cited by this paper
• Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?

  2009cited by this paper
• Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

  2009cited by this paper
• Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes.

  2009cited by this paper
• Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

  2009cited by this paper
• Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

  2008cited by this paper
• Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

  2008cited by this paper
• Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group

  2008cited by this paper
• A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer

  2008influential reference
• Anthracycline cardiotoxicity: from bench to bedside.

  2008cited by this paper
• A Phase I dose-escalation study to determine the maximum tolerated dose of erlotinib when combined with pertuzumab in previously treated non-small-cell lung cancer patients.

  2008cited by this paper
• A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors

  2008influential reference
• Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition

  2008cited by this paper
• Cardiac toxicity of ErbB2-targeted therapies: what do we know?

  2008cited by this paper
• Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.

  2008cited by this paper
• Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.

  2007cited by this paper
• Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

  2007cited by this paper
• A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

  2007influential reference
• Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

  2007influential reference
• Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.

  2007cited by this paper
• Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T

  2007cited by this paper
• Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

  2007cited by this paper
• Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

  2007influential reference
• Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.

  2006cited by this paper
• Herceptin and the heart--a molecular modifier of cardiac failure.

  2006cited by this paper
• Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

  2006influential reference
• Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition

  2006cited by this paper
• Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.

  2005cited by this paper
• Neuregulin-1 Induces a Negative Inotropic Effect in Cardiac Muscle: Role of Nitric Oxide Synthase

  2004cited by this paper
• Neuregulins Regulate Cardiac Parasympathetic Activity: Muscarinic Modulation of &bgr;-Adrenergic Activity in Myocytes From Mice With Neuregulin-1 Gene Deletion

  2004cited by this paper
• Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

  2003cited by this paper
• Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

  2002cited by this paper
• Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1&bgr; and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity

  2002cited by this paper
• Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2–ErbB3 receptors

  2002cited by this paper
• ErbB2 is essential in the prevention of dilated cardiomyopathy

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70S6K, and MEK-MAPK-RSK.

  1999cited by this paper
• Neuregulins Promote Survival and Growth of Cardiac Myocytes

  1998cited by this paper
• A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

  1996cited by this paper
• Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor

  1995cited by this paper
• Requirement for neuregulin receptor erbB2 in neural and cardiac development

  1995cited by this paper

• Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document

  2025cites this paper
• Real-world disproportionality analysis of cardiac failure associated with novel antineoplastic agents in breast cancer: a pharmacovigilance study

  2025cites this paper
• Cardiotoxicity of breast cancer drug treatments

  2025cites this paper
• Kardiotoxizität zielgerichteter onkologischer Therapien

  2024cites this paper
• Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA)

  2024cites this paper
• Role of the Tumor Microenvironment in Mediating Resistance to Anti-HER2 Antibodies.

  2024cites this paper
• Cardiotoxicity of Anti-Cancer Radiation Therapy: a Focus on Heart Failure

  2023cites this paper
• Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine

  2023influential citation
• Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system

  2023influential citation
• Cardiotoxicity in breast cancer treatment: Causes and mitigation.

  2023cites this paper
• Pertuzumab-mediated Cardiotoxicity: A Single Center Study.

  2023cites this paper
• Kardiotoxizität zielgerichteter onkologischer Therapien

  2023cites this paper
• Opportunities and Challenges in Cardio-Oncology:A Bibliometric analysis From 2010 to 2022.

  2022cites this paper
• Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review.

  2022cites this paper
• Myocardial Dysfunction in Patients with Cancer.

  2022cites this paper
• Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data

  2022cites this paper
• Cardiac Toxicity From Adjuvant Targeting Treatment for Breast Cancer Post-Surgery

  2022cites this paper
• Towards the use of localised delivery strategies to counteract cancer therapy–induced cardiotoxicities

  2021cites this paper
• Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer

  2021cites this paper
• Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers

  2021cites this paper
• Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis

  2021cites this paper
• Efficacy, patterns of use and cost of Pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience

  2020cites this paper
• Srčno popuščanje in onkološko zdravljenje

  2020cites this paper
• Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors

  2020cites this paper
• Complications cardiaques des traitements anticancéreux

  2020cites this paper
• Studies of side effects related to adjuvant breast cancer regimens with focus on chemotherapy

  2020cites this paper
• Personalized Approach to Cancer Treatment–Related Cardiomyopathy

  2020cites this paper
• Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.

  2019cites this paper
• Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

  2019cites this paper
• Cardio-Oncology: Vascular and Metabolic Perspectives A Scientific Statement From the American Heart Association

  2019cites this paper
• Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio‐Oncology

  2019cites this paper
• Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.

  2019cites this paper
• Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I

  2018cites this paper
• Cardiotoxicity of Novel Targeted Chemotherapeutic Agents

  2018cites this paper
• Side Effects of Medical Cancer Therapy

  2018cites this paper
• Cardiovascular sequelae of breast cancer treatments: A review.

  2018cites this paper
• Risk of regorafenib-induced cardiovascular events in patients with solid tumors

  2018cites this paper
• Cardio-oncology: Understanding cardiotoxicity to guide patient focused imaging

  2018cites this paper
• Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents

  2018cites this paper
• Cardiovascular Disease and Breast Cancer: Where These Entities Intersect A Scientific Statement From the American Heart Association

  2018cites this paper
• Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.

  2018cites this paper
• Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results

  2017cites this paper
• Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.

  2017cites this paper
• Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab

  2017cites this paper
• Heart failure following oncological treatment

  2017cites this paper
• Association analysis of polymorphisms in EGFR, HER2, ESR1 and THRA genes with coronary artery diseases

  2017cites this paper
• Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients

  2017cites this paper
• Changes of Myocardial Structure and Function

  2017cites this paper
• Twenty years of anti-HER2 therapy-associated cardiotoxicity

  2016influential citation
• [2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines].

  2016cites this paper
• Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

  2016cites this paper
• Kinase inhibitors and monoclonal antibodies in oncology: clinical implications

  2016cites this paper
• An emerging epidemic: cancer and heart failure.

  2016cites this paper
• Pertuzumab for the treatment of breast cancer: a safety review

  2016cites this paper
• Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association.

  2016cites this paper
• Human epidermal growth factor antagonists and cardiotoxicity-A short review of the problem and preventative measures.

  2016cites this paper
• Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.

  2016cites this paper
• 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

  2016cites this paper
• 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

  2016cites this paper
• Approaches to Endow Ribonucleases with Antitumor Activity: Lessons Learned from the Native Cytotoxic Ribonucleases

  2016cites this paper
• Chapter 8 – Chemotherapy-Induced Cardiomyopathy

  2016cites this paper
• Radiation therapy, including internal mammary nodal irradiation, and heart failure in patients receiving concurrent treatment with trastuzumab

  2016cites this paper
• ErbB2 signaling at the crossing between heart failure and cancer

  2016cites this paper
• Dual HeR 2 blockade in the neoadjuvant and adjuvant treatment of HeR 2-positive breast cancer

  2015cites this paper
• Chemotherapy Induced Cardiomyopathy

  2015cites this paper
• Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients

  2015cites this paper
• Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.

  2015cites this paper
• Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer

  2015cites this paper
• Pertuzumab et T-DM1 : de nouvelles perspectives dans le traitement du cancer du sein HER2 positif

  2015influential citation
• Cáncer de mama metastásico

  2015cites this paper
• Pertuzumab in the Treatment of HER 2 + Breast Cancer

  2014cites this paper
• Evaluation and management of patients with heart disease and cancer: cardio-oncology.

  2014cites this paper
• Pertuzumab: A New Targeted Therapy for HER2‐Positive Metastatic Breast Cancer

  2014influential citation
• Anti-HER2 cancer therapy and cardiotoxicity.

  2014cites this paper
• Therapeutic Considerations When Treating HER2-positive Metastatic Breast Cancer

  2014cites this paper
• Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.

  2014cites this paper
• Pertuzumab in the treatment of HER2+ breast cancer.

  2014cites this paper
• Reversibility of effectively treated chemotherapy-related heart failure: raising our awareness and a call to action for cardiology.

  2014cites this paper
• Cardiotoxicity of Molecularly Targeted Chemotherapeutic Agents

  2014cites this paper
• A case report of takotsubo cardiomyopathy occurring during chemotherapy with trastuzumab

  2014cites this paper
• An update on cardio-oncology.

  2014influential citation
• Cardiotoxicity of systemic agents used in breast cancer.

  2014cites this paper
• Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

  2014cites this paper
• Cancer du sein métastatique

  2014cites this paper
• Complications cardiaques des maladies malignes et de leurs traitements

  2014cites this paper
• Pertuzumab for the treatment of metastatic breast cancer

  2013cites this paper
• Pertuzumab beim metastasierten HeR2-positiven mammakarzinom

  2013cites this paper
• Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.

  2013cites this paper
• Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure

  2013cites this paper
• HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

  2013cites this paper
• Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.

  2013cites this paper
• Cardiovascular toxicities of cancer chemotherapy.

  2013cites this paper
• Pertuzumab in breast cancer: a systematic review.

  2013cites this paper
• The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics.

  2013cites this paper
• Chemotherapy-related cardiotoxicity

  2013cites this paper
• Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

  2013cites this paper
• Understanding, recognizing, and managing toxicities of targeted anticancer therapies

  2013cites this paper
• Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .

  2013cites this paper
• Emerging paradigms in cardiomyopathies associated with cancer therapies.

  2013cites this paper
• Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.

  2013cites this paper